Browse EX-10 agreements

Exhibit 10.1

[●], 2026

Aeon Acquisition I Corp.

66 West Flagler Street, Suite 900

Miami, FL 33130

Re: Initial Public Offering

Ladies and Gentlemen:

This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and among Aeon Acquisition I Corp., a Cayman Islands exempted company (the “Company”), and D. Boral Capital LLC, as representative (the “Representative”) of the underwriters (the “Underwriters”), relating to an underwritten initial public offering (the “Public Offering”), of up to 14,375,000 of the Company’s units (including up to 1,875,000 units which may be purchased to cover over-allotments, if any) (the “Units”), each comprised of one Class A ordinary share, par value $0.0001 per share, of the Company (the “Class A Ordinary Shares”), one redeemable warrant of the Company (each whole warrant, a “Warrant”), with each Warrant entitling the holder to purchase one Class A Ordinary

…

SMRH:4916-0741-5978.4 -2- security" (as such term is defined in Rule 3a11-1 of the General Rules and Regulations promulgated by the Securities and Exchange Commission under the Securities Exchange Act of 1934). "Event of Default" is defined in Section 6. "Initial Pledged Shares" means those initial Pledged Shares described on Schedule 1 attached to this Agreement, and all Equity Interests related thereto. "Issuer" means the Company. "Pledged Shares" means Shares of the Company in which a security interest has been granted to Secured Party pursuant to this Agreement as security for the Secured Obligations, including, without limitation, (a) Initial Pledged Shares and (b) Shares otherwise constituting Proceeds of Pledged Shares. "Proceeds" means all proceeds (including proceeds of proceeds) of any of the Collateral including all: (a) rights, benefits, distributions, premiums, profits, dividends, interest, cash, instruments, documents of title, accounts, contract rights, inventory, equipment, general intangibles, payment intangibles, deposit accounts, chattel paper, and other property f

…

PURCHASE AND SALE AGREEMENT

THIS PURCHASE AND SALE AGREEMENT (this “Agreement”) by and between NATIONAL HEALTH CORPORATION, a Tennessee corporation (“Seller”), and NHC/OP, L.P., a Delaware limited partnership (“Buyer”), is effective as of May 14, 2026 (“Effective Date”).

RECITALS

A.    Seller is the owner of certain Property (as defined below) generally known as 815 South Walnut Avenue, Cookeville, Putnam County, TN; 374 Brink Street, Lawrenceburg, Lawrence County, TN; 420 N. University Street, Murfreesboro, Rutherford County, TN; 300 Laboratory Road, Oak Ridge, Anderson County, TN; and 1018 N. Guignard Drive, Sumter, Sumter County, SC.

B.    Each Property is improved with a skilled nursing facility of which Seller is the licensed operator (each, a “Facility”, and collectively, the “Facilities”).

…

January 13, 2022

Kevin P. O’Brien

Dear Kevin,

We are pleased to offer you the position of Corporate Controller & Chief Accounting Officer with Hydrofarm Holdings Group, Inc. (the “Company”) reporting directly to me. This is an exempt position with an annual base salary of Three Hundred Thousand Dollars ($300,000.00) which will be paid in bi-weekly increments as earned and in accordance with the Company’s normal payroll procedures.

Your start date will be agreed by both parts and documented on separate communication. You will be part of Hydrofarm’s annual performance review cycle and be eligible to earn an annual performance bonus of up to fifty percent (50%). The Annual Bonus will be based upon the Board’s assessment of your performance and the Company’s attainment of goals, including annual EBITDA versus target EBITDA, as determined by the Board. For Fiscal Year 2022, Seventy Five Thousand Dollars ($75,000.00) of the Annual Bonus is guaranteed and will be paid in accordance with the Company’s payout date.

…

Tyler Zeronda

33 Hall Rd

Chatham NJ 07928

Re:    Yarrow Bioscience, Inc. – Employment Offer

Dear Tyler,

Contingent upon the completion of the transactions contemplated by that certain Agreement and Plan of Merger and Reorganization, dated as of December 17, 2025, and amended on January 30, 2026, by and among VYNE Therapeutics Inc., Yarrow Bioscience, Inc., and Yellow Merger Sub Corp. (the “Merger”), on behalf of VYNE Therapeutics, Inc. (to be renamed Yarrow Bioscience, Inc. following the Merger) (the “Company”), we are very pleased to offer you a position as Chief Financial Officer of the Company (“CFO”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below, to be effective as of, and contingent upon, the closing of the Merger (the “Effective Date”).

…

AMENDED AND RESTATED

CHANGE IN CONTROL SEVERANCE AGREEMENT

THIS AMENDED AND RESTATED CHANGE IN CONTROL SEVERANCE AGREEMENT (the “Agreement”) is entered into on [________________], between [________________] (“Executive”) and AEye, Inc., a Delaware corporation (the “Company”).

WHEREAS, this Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events after the date hereof.

NOW THEREFORE, the Company and Executive hereby agree as follows:

ARTICLE I

EMPLOYMENT BY THE COMPANY

1.1 Executive is currently employed as an executive of the Company.

1.2 This Agreement shall remain in full force and effect during the term of Executive’s employment with the Company, unless amended pursuant to Section 7.7.

1.3 The Company and Executive wish to set forth the compensation and benefits which Executive shall be entitled to receive if Executive’s employment with the Company terminates under the circumstances described in Article II of this Agreement.

…

Exhibit 10.1

BRANCHOUT FOOD INC.

Second Amended and Restated

Senior Secured Promissory Note

$3,000,000		January 28, 2026 (the “Issue Date”)
		As amended and restated on April 17, 2026
		As further amended and restated on May 15, 2026

FOR VALUE RECEIVED, BRANCHOUT FOOD, INC., a Nevada corporation (the “Company”) with its principal executive office at 205 SE Davis Ave., Suite C, Bend, Oregon 97702, promises to pay to the order of Kaufman Kapital LLC, a Delaware limited liability company, or its registered assigns (the “Holder” or “Payee”), the principal amount of Three Million Dollars ($3,000,000) (the “Principal Amount”), together with interest on such Principal Amount, on January 28, 2027 (the “Maturity Date”). Interest on this Second Amended and Restated Senior Secured Promissory Note (this “Note”) shall accrue on the Principal Amount outstanding at a rate per annum computed in accordance with Section 2 hereof. This Note represents

…

Exhibit 10.12

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (this “Agreement”), dated April 28, 2026 (the “Effective Date”), is entered into by and between BioVentrix, Inc. (the “Company”) and Carl Byrnes (the “Executive”).

WHEREAS, the Company and the Executive desire to enter into an agreement that embodies the terms of such employment and that supersedes and replaces the Offer Letter, subject to the terms and conditions of this Agreement.

NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:

Employment Period. The Company shall employ the Executive pursuant to this Agreement for a term (the “Employment Period”) commencing on the Effective Date and continuing indefinitely until terminated by either party in accordance with the provisions of Section 3 hereof. As of the Effective Date, the Offer Letter is superseded and replaced in its entirety.

Terms of Employment.

a. Position and Duties.

…

Exhibit 10.11

CONSULTING AGREEMENT

This Agreement is made effective as of September 20, 2022 (the “Effective Date”) by and between BioVentrix, Inc., a Delaware corporation, with its principal place of business at 12647 Alcosta Blvd., Suite 400, San Ramon, CA 94583 (the “Company”), and Ori Ben-Yehuda M.D. (dba as Ori Ben-Yehuda Consulting LLC) 44 Oak Road, Katonah, NY 10536 (“Consultant”).

RECITAL

Consultant desires to perform, and the Company desires to have Consultant perform, consulting services as an independent contractor to the Company.

NOW, THEREFORE, the parties agree as follows:

I. Services.

…

FIRST AMENDMENT TO LICENSE AGREEMENT

This FIRST AMENDMENT (the “First Amendment”) is made and entered into as of May 14, 2026 (“First Amendment Effective Date”), by and between BioAtla, Inc., a Delaware corporation (“BioAtla”), and Context Therapeutics Inc., a Delaware corporation (“Context”). Each of BioAtla and Context is sometimes referred to individually in this First Amendment as a “Party” and collectively as the “Parties.”

WHEREAS, BioAtla and Context are parties to that certain License Agreement, dated September 23, 2024 (the “Agreement”);

…

Exhibit 10.5

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL

REMUNERATED PRIVATE INVESTMENT AGREEMENT

In Madrid, Spain on March 30th, 2026.

PARTIES

On the one hand

Mr. Rafael Jesús Contreras Chamorro with ID NUM. [***], acting in the name and on behalf of the company NOMADAR CORP, with TAX ID EIN: 99-3383359, domiciled for these purposes in United States, in the State of Texas is 5015 Hwy 59 N, Marshall, 75670.

And, on the other hand

…

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL

REMUNERATED PRIVATE INVESTMENT AGREEMENT

In Madrid, Spain on March 4th, 2026.

PARTIES

On the one hand

Mr. Rafael Jesús Contreras Chamorro with ID NUM. [***], acting in the name and on behalf of the company NOMADAR CORP, with TAX ID EIN: 99-3383359, domiciled for these purposes in United States, in the State of Texas is 5015 Hwy 59 N, Marshall, 75670.

And, on the other hand

…